首页> 外文期刊>Molecular cancer research: MCR >Stress chaperone GRP78/BiP confers chemoresistance to tumor-associated endothelial cells.
【24h】

Stress chaperone GRP78/BiP confers chemoresistance to tumor-associated endothelial cells.

机译:应激伴侣GRP78 / BiP赋予与肿瘤相关的内皮细胞化学耐药性。

获取原文
获取原文并翻译 | 示例
           

摘要

The tumor vasculature is essential for tumor growth and survival and is a key target for anticancer therapy. Glioblastoma multiforme, the most malignant form of brain tumor, is highly vascular and contains abnormal vessels, unlike blood vessels in normal brain. Previously, we showed that primary cultures of human brain endothelial cells, derived from blood vessels of malignant glioma tissues (TuBEC), are physiologically and functionally different from endothelial cells derived from nonmalignant brain tissues (BEC) and are substantially more resistant to apoptosis. Resistance of TuBEC to a wide range of current anticancer drugs has significant clinical consequences as it represents a major obstacle toward eradication of residual brain tumor. We report here that the endoplasmic reticulum chaperone GRP78/BiP is generally highly elevated in the vasculature derived from human glioma specimens, both in situ in tissue and in vitro in primary cell cultures, compared with minimal GRP78 expression in normal brain tissues and blood vessels. Interestingly, TuBEC constitutively overexpress GRP78 without concomitant induction of other major unfolded protein response targets. Resistance of TuBEC to chemotherapeutic agents such as CPT-11, etoposide, and temozolomide can be overcome by knockdown of GRP78 using small interfering RNA or chemical inhibition of its catalytic site. Conversely, overexpression of GRP78 in BEC rendered these cells resistant to drug treatments. Our findings provide the proof of principle that targeting GRP78 will sensitize the tumor vasculature to chemotherapeutic drugs, thus enhancing the efficacy of these drugs in combination therapy for glioma treatment.
机译:肿瘤脉管系统对于肿瘤的生长和存活是必不可少的,并且是抗癌治疗的关键靶标。多形性胶质母细胞瘤是脑肿瘤的最恶性形式,具有高度血管性,并且包含异常血管,这与正常大脑中的血管不同。以前,我们显示,源自恶性神经胶质瘤组织(TuBEC)血管的人脑内皮细胞的原代培养物在生理和功能上与源自非恶性脑组织(BEC)的内皮细胞不同,并且对凋亡的抵抗力明显更高。 TuBEC对多种当前抗癌药物的耐药性具有重大的临床后果,因为它是消除残留脑瘤的主要障碍。我们在这里报告,与正常脑组织和血管中的最小GRP78表达相比,内质网伴侣GRP78 / BiP在人神经胶质瘤标本的脉管系统中在原位组织和原代细胞培养中通常高度升高。有趣的是,TuBEC组成型过表达GRP78,而没有同时诱导其他主要的未折叠蛋白应答靶标。 TuBEC对化学治疗剂(如CPT-11,依托泊苷和替莫唑胺)的耐药性可通过使用小分子干扰RNA敲低GRP78或对其催化位点进行化学抑制来克服。相反,BEC中GRP78的过度表达使这些细胞对药物治疗具有抗性。我们的发现提供了原理上的证明,即靶向GRP78将使肿瘤脉管系统对化疗药物敏感,从而增强这些药物在神经胶质瘤联合治疗中的疗效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号